Published in Pharmacol Biochem Behav on October 25, 2008
Fluorocurcumins as cyclooxygenase-2 inhibitor: molecular docking, pharmacokinetics and tissue distribution in mice. Pharm Res (2009) 1.48
New difluoro Knoevenagel condensates of curcumin, their Schiff bases and copper complexes as proteasome inhibitors and apoptosis inducers in cancer cells. Pharm Res (2009) 1.42
Neurobiology of chronic mild stress: parallels to major depression. Neurosci Biobehav Rev (2012) 1.41
Difluorinated-curcumin (CDF): a novel curcumin analog is a potent inhibitor of colon cancer stem-like cells. Pharm Res (2010) 1.22
Control of biogenic amines in food--existing and emerging approaches. J Food Sci (2010) 1.17
Perspectives on chemopreventive and therapeutic potential of curcumin analogs in medicinal chemistry. Mini Rev Med Chem (2010) 1.17
An overview of curcumin in neurological disorders. Indian J Pharm Sci (2010) 1.04
Bioavailability enhancers of herbal origin: an overview. Asian Pac J Trop Biomed (2013) 1.01
Neuroinflammation, neurodegeneration, and depression. Neurotox Res (2012) 0.95
Antidepressant-like effects of curcumin in WKY rat model of depression is associated with an increase in hippocampal BDNF. Behav Brain Res (2012) 0.90
Piperine suppresses tumor growth and metastasis in vitro and in vivo in a 4T1 murine breast cancer model. Acta Pharmacol Sin (2012) 0.89
Chronic depression as a model disease for cerebral aging. Dialogues Clin Neurosci (2013) 0.84
Piperine potentiates the hypocholesterolemic effect of curcumin in rats fed on a high fat diet. Exp Ther Med (2014) 0.82
Turmeric active substance, curcumin, enhanced apomorphine-induced yawning in rats. Avicenna J Phytomed (2013) 0.82
Prevention and Treatment of Colorectal Cancer by Natural Agents From Mother Nature. Curr Colorectal Cancer Rep (2013) 0.80
Protective effects of curcumin against rotenone and salsolinol-induced toxicity: implications for Parkinson's disease. Neurotox Res (2014) 0.79
Antidepressant-like activity of turmerone in behavioral despair tests in mice. BMC Complement Altern Med (2013) 0.78
A diet enriched with curcumin impairs newly acquired and reactivated fear memories. Neuropsychopharmacology (2015) 0.78
Duality of Antidepressants and Neuroprotectants. Neurotox Res (2015) 0.77
The development of injectable gelatin/silk fibroin microspheres for the dual delivery of curcumin and piperine. J Mater Sci Mater Med (2013) 0.77
The antinociceptive effects of ferulic acid on neuropathic pain: involvement of descending monoaminergic system and opioid receptors. Oncotarget (2016) 0.76
Improvement of bioavailability and anti-inflammatory potential of curcumin in combination with emu oil. Inflammation (2014) 0.76
Traditional Chinese medicine and Western psychopharmacology: building bridges. Phytother Res (2013) 0.75
Curcumin reverses neurochemical, histological and immuno-histochemical alterations in the model of global brain ischemia. J Tradit Complement Med (2016) 0.75
Piperine Attenuates Pathological Cardiac Fibrosis Via PPAR-γ/AKT Pathways. EBioMedicine (2017) 0.75
Effects of curcumin on glucose metabolism in the brains of rats subjected to chronic unpredictable stress: a 18 F-FDG micro-PET study. BMC Complement Altern Med (2013) 0.75
Antidepressant effects of curcumin and HU-211 coencapsulated solid lipid nanoparticles against corticosterone-induced cellular and animal models of major depression. Int J Nanomedicine (2016) 0.75
Effects of Yulangsan polysaccharide on monoamine neurotransmitters, adenylate cyclase activity and brain-derived neurotrophic factor expression in a mouse model of depression induced by unpredictable chronic mild stress. Neural Regen Res (2012) 0.75
Therapeutic Effects of Phytochemicals and Medicinal Herbs on Depression. Biomed Res Int (2017) 0.75
Synergistic antidepressant-like effect of ferulic acid in combination with piperine: involvement of monoaminergic system. Metab Brain Dis (2015) 0.75
Dose-dependent effect of Curcuma longa for the treatment of Parkinson's disease. Exp Ther Med (2017) 0.75
Curcumin, demethoxycurcumin and bisdemethoxycurcumin differentially inhibit morphine's rewarding effect in rats. Psychopharmacology (Berl) (2014) 0.75
Curcumin, the active principle of turmeric (Curcuma longa), ameliorates diabetic nephropathy in rats. Clin Exp Pharmacol Physiol (2006) 1.38
Effect of insulin and its combination with resveratrol or curcumin in attenuation of diabetic neuropathic pain: participation of nitric oxide and TNF-alpha. Phytother Res (2007) 1.30
Minocycline prevents the development of neuropathic pain, but not acute pain: possible anti-inflammatory and antioxidant mechanisms. Eur J Pharmacol (2008) 1.27
Antidepressant activity of curcumin: involvement of serotonin and dopamine system. Psychopharmacology (Berl) (2008) 1.21
Effect of natural and synthetic antioxidants in a mouse model of chronic fatigue syndrome. J Med Food (2002) 1.14
Suppression of NF-kappabeta signaling pathway by tocotrienol can prevent diabetes associated cognitive deficits. Pharmacol Biochem Behav (2008) 1.08
Minocycline attenuates the development of diabetic neuropathic pain: possible anti-inflammatory and anti-oxidant mechanisms. Eur J Pharmacol (2011) 1.05
Isobolographic analysis of interaction between cyclooxygenase inhibitors and tramadol in acetic acid-induced writhing in mice. Prog Neuropsychopharmacol Biol Psychiatry (2004) 0.99
Modulatory role of cyclooxygenase inhibitors in aging- and scopolamine or lipopolysaccharide-induced cognitive dysfunction in mice. Behav Brain Res (2002) 0.99
Chronic treatment with tocotrienol, an isoform of vitamin E, prevents intracerebroventricular streptozotocin-induced cognitive impairment and oxidative-nitrosative stress in rats. Pharmacol Biochem Behav (2009) 0.95
Reversal of aging and chronic ethanol-induced cognitive dysfunction by quercetin a bioflavonoid. Free Radic Res (2003) 0.94
Comparative behavioural profile of newer antianxiety drugs on different mazes. Indian J Exp Biol (2008) 0.94
Modulatory effect of the PDE-5 inhibitor sildenafil in diabetic neuropathy. Pharmacology (2004) 0.94
Activation characteristics of transient receptor potential ankyrin 1 and its role in nociception. Am J Physiol Cell Physiol (2011) 0.93
Effect of Withania somnifera root extract on haloperidol-induced orofacial dyskinesia: possible mechanisms of action. J Med Food (2003) 0.93
Protective effect of naproxen (non-selective COX-inhibitor) or rofecoxib (selective COX-2 inhibitor) on immobilization stress-induced behavioral and biochemical alterations in mice. Eur J Pharmacol (2006) 0.93
Carvedilol attenuates neuroleptic-induced orofacial dyskinesia: possible antioxidant mechanisms. Br J Pharmacol (2002) 0.93
Expression of transient receptor potential ankyrin 1 (TRPA1) and its role in insulin release from rat pancreatic beta cells. PLoS One (2012) 0.93
Protective effect of Curcumin, the active principle of turmeric (Curcuma longa) in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes in rat brain. Pharmacol Biochem Behav (2007) 0.93
Modulation of NSAID-induced antinociceptive and anti-inflammatory effects by alpha2-adrenoceptor agonists with gastroprotective effects. Life Sci (2002) 0.92
Blockade of CRF1 receptors in the central nucleus of the amygdala attenuates the dysphoria associated with nicotine withdrawal in rats. Pharmacol Biochem Behav (2011) 0.92
Protective effect of flavonoids against aging- and lipopolysaccharide-induced cognitive impairment in mice. Pharmacology (2003) 0.92
Aggravation of inflammatory bowel disease by cyclooxygenase-2 inhibitors in rats. Pharmacology (2004) 0.90
Disease-related changes in TRPV1 expression and its implications for drug development. Curr Top Med Chem (2011) 0.90
Effect of resveratrol, a polyphenolic phytoalexin, on thermal hyperalgesia in a mouse model of diabetic neuropathic pain. Fundam Clin Pharmacol (2007) 0.89
Curcumin pretreatment protects against acute acrylonitrile-induced oxidative damage in rats. Toxicology (2009) 0.88
Quercetin, a bioflavonoid, attenuates haloperidol-induced orofacial dyskinesia. Neuropharmacology (2003) 0.87
Sildenafil, a phosphodiesterase-5 inhibitor, enhances the antinociceptive effect of morphine. Pharmacology (2003) 0.87
Modulatory effect of sildenafil in diabetes and electroconvulsive shock-induced cognitive dysfunction in rats. Pharmacol Rep (2006) 0.87
Pharmacological profile of parecoxib: a novel, potent injectable selective cyclooxygenase-2 inhibitor. Eur J Pharmacol (2004) 0.87
Effect of nimesulide on acetic acid- and leukotriene-induced inflammatory bowel disease in rats. Prostaglandins Other Lipid Mediat (2003) 0.86
Effects of prazosin, clonidine, and propranolol on the elevations in brain reward thresholds and somatic signs associated with nicotine withdrawal in rats. Psychopharmacology (Berl) (2010) 0.86
Potentiation of antinociceptive effect of NSAIDs by a specific lipooxygenase inhibitor, acetyl 11-keto-beta boswellic acid. Indian J Exp Biol (2006) 0.85
Co-administration of acetyl-11-keto-beta-boswellic acid, a specific 5-lipoxygenase inhibitor, potentiates the protective effect of COX-2 inhibitors in kainic acid-induced neurotoxicity in mice. Pharmacology (2006) 0.85
Effect of naproxen, a non-selective cyclo-oxygenase inhibitor, on pentylenetetrazol-induced kindling in mice. Clin Exp Pharmacol Physiol (2005) 0.85
Differential effects of naproxen and rofecoxib on the development of hypersensitivity following nerve injury in rats. Pharmacol Biochem Behav (2004) 0.85
Preadolescent tobacco smoke exposure leads to acute nicotine dependence but does not affect the rewarding effects of nicotine or nicotine withdrawal in adulthood in rats. Pharmacol Biochem Behav (2010) 0.85
Effect of selective inhibition of cyclooxygenase-2 on lipopolysaccharide-induced hyperalgesia. Inflammopharmacology (2004) 0.84
Reversal of reserpine-induced orofacial dyskinesia and cognitive dysfunction by quercetin. Pharmacology (2004) 0.84
Protective effect of minocycline, a semi-synthetic second-generation tetracycline against 3-nitropropionic acid (3-NP)-induced neurotoxicity. Toxicology (2007) 0.84
Evidence for serotonergic modulation of progesterone-induced hyperphagia, depression and algesia in female mice. Brain Res (2002) 0.83
Effect of cyclooxygenase inhibitors on pentylenetetrazol (PTZ)-induced convulsions: Possible mechanism of action. Prog Neuropsychopharmacol Biol Psychiatry (2006) 0.83
Differential effect of zileuton, a 5-lipoxygenase inhibitor, against nociceptive paradigms in mice and rats. Pharmacol Biochem Behav (2005) 0.83
Peripheral and central activation of nitric oxide-cyclic GMP pathway by sildenafil. Inflammopharmacology (2005) 0.83
Anti-inflammatory effect of licofelone against various inflammatory challenges. Fundam Clin Pharmacol (2006) 0.83
Neuroprotective effect of nimesulide, a preferential COX-2 inhibitor, against pentylenetetrazol (PTZ)-induced chemical kindling and associated biochemical parameters in mice. Seizure (2007) 0.82
Evaluation of anti-hyperglycemic activity of some novel monocyclic beta lactams. J Pharm Pharm Sci (2004) 0.81
Possible mechanisms of action in quercetin reversal of morphine tolerance and dependence. Addict Biol (2003) 0.81
Modulatory effect of cyclooxygenase inhibitors on sildenafil-induced antinociception. Pharmacology (2003) 0.81
Quercetin potentiates L-Dopa reversal of drug-induced catalepsy in rats: possible COMT/MAO inhibition. Pharmacology (2003) 0.81
Theophylline, adenosine receptor antagonist prevents behavioral, biochemical and neurochemical changes associated with an animal model of tardive dyskinesia. Pharmacol Rep (2007) 0.81
Possible anti-oxidant and neuroprotective mechanisms of zolpidem in attenuating typical anti-psychotic-induced orofacial dyskinesia: a biochemical and neurochemical study. Prog Neuropsychopharmacol Biol Psychiatry (2007) 0.80
Studies on modulation of feeding behavior by atypical antipsychotics in female mice. Prog Neuropsychopharmacol Biol Psychiatry (2002) 0.80
Protective effect of L-type calcium channel blockers against haloperidol-induced orofacial dyskinesia: a behavioural, biochemical and neurochemical study. Neurochem Res (2008) 0.80
Protective effect of adenosine reuptake inhibitors in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes. Pharmacology (2007) 0.79
Involvement of adenosinergic receptor system in an animal model of tardive dyskinesia and associated behavioural, biochemical and neurochemical changes. Eur J Pharmacol (2006) 0.79
D2-dopamine receptor and alpha2-adrenoreceptor-mediated analgesic response of quercetin. Indian J Exp Biol (2003) 0.79
Effect of zileuton in radicular pain induced by herniated nucleus pulposus in rats. Inflammopharmacology (2004) 0.79
Effect of Withania somnifera root extract on reserpine-induced orofacial dyskinesia and cognitive dysfunction. Phytother Res (2006) 0.79
Differential striatal levels of TNF-alpha, NFkappaB p65 subunit and dopamine with chronic typical and atypical neuroleptic treatment: role in orofacial dyskinesia. Prog Neuropsychopharmacol Biol Psychiatry (2008) 0.78
Analysis of interaction between etoricoxib and tramadol against mechanical hyperalgesia of spinal cord injury in rats. Life Sci (2005) 0.78
Possible mechanism of action in melatonin attenuation of haloperidol-induced orofacial dyskinesia. Pharmacol Biochem Behav (2003) 0.78
Effect of licofelone against NSAIDs-induced gastrointestinal ulceration and inflammation. Indian J Exp Biol (2005) 0.78
Protective effect of rutin, a polyphenolic flavonoid against haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes. Fundam Clin Pharmacol (2007) 0.78
Progesterone attenuates neuroleptic-induced orofacial dyskinesia via the activity of its metabolite, allopregnanolone, a positive GABA(A) modulating neurosteroid. Prog Neuropsychopharmacol Biol Psychiatry (2007) 0.78
Anti-nociceptive effect of duloxetine in mouse model of diabetic neuropathic pain. Indian J Exp Biol (2009) 0.78
Cholinergic-NO-cGMP mediation of sildenafil-induced antinociception. Indian J Exp Biol (2004) 0.78
Inflammatory and neurochemical changes associated with 3-nitropropionic Acid neurotoxicity. Toxicol Mech Methods (2008) 0.78
Co-administration of nitric oxide (NO) donors prevents haloperidol-induced orofacial dyskinesia, oxidative damage and change in striatal dopamine levels. Pharmacol Biochem Behav (2008) 0.78
Failure of FK506 (tacrolimus) to alleviate apomorphine-induced circling in rat Parkinson model in spite of some cytoprotective effects in SH-SY5Y dopaminergic cells. Brain Res (2005) 0.77
Protective effect of cyclooxygenase-2 (COX-2) inhibitors but not non-selective cyclooxygenase (COX)-inhibitors on ethanol withdrawal-induced behavioural changes. Addict Biol (2005) 0.77
Involvement of adenosinergic receptors in anxiety related behaviours. Indian J Exp Biol (2007) 0.77
Differential effects of cyclooxygenase inhibitors on haloperidol-induced catalepsy. Prog Neuropsychopharmacol Biol Psychiatry (2002) 0.77
Effect of rofecoxib, a cyclo-oxygenase-2 inhibitor, on various biochemical parameters of brain associated with pentylenetetrazol-induced chemical kindling in mice. Fundam Clin Pharmacol (2006) 0.77
Paradoxical effects of opioid antagonist naloxone on SSRI-induced analgesia and tolerance in mice. Pharmacology (2003) 0.77
Activation of striatal inflammatory mediators and caspase-3 is central to haloperidol-induced orofacial dyskinesia. Eur J Pharmacol (2008) 0.77
Inhibitory effect of sildenafil on gastrointestinal smooth muscle: role of NO-cGMP transduction pathway. Indian J Exp Biol (2005) 0.77
Effect of cyclooxygenase-2 (COX-2) inhibitors in various animal models (bicuculline, picrotoxin, maximal electroshock-induced convulsions) of epilepsy with possible mechanism of action. Indian J Exp Biol (2006) 0.77
Comparative neurochemical changes associated with chronic administration of typical and atypical neuroleptics: implications in tardive dyskinesia. Indian J Exp Biol (2007) 0.76
Protective effect of curcumin and its combination with piperine (bioavailability enhancer) against haloperidol-associated neurotoxicity: cellular and neurochemical evidence. Neurotox Res (2010) 0.76
Effect of systemic administration of adenosine on brain adenosine levels in pentylenetetrazol-induced seizure threshold in mice. Neurosci Lett (2007) 0.76
Role of cyclooxygenase-2 in lipopolysaccharide-induced hyperalgesia in formalin test. Indian J Exp Biol (2005) 0.76
Effect of licofelone against mechanical hyperalgesia and cold allodynia in the rat model of incisional pain. Pharmacol Rep (2005) 0.76
Development and validation of an RP-HPLC method for the estimation of adenosine and related purines in brain tissues of rats. J Sep Sci (2008) 0.76
Effect of FK506 (tacrolimus) in animal models of inflammation. Inflammopharmacology (2003) 0.75
In vivo microdialysis studies of striatal level of neurotransmitters after haloperidol and chlorpromazine administration. Indian J Exp Biol (2009) 0.75
Effect of 5-lipoxygenase inhibitor against lipopolysaccharide-induced hypothermia in mice. Indian J Exp Biol (2005) 0.75
An activity model for novel antidepressants that interact with the serotonin transporter (SERT). Cent Nerv Syst Agents Med Chem (2011) 0.75
PASS assisted search and evaluation of some azetidin-2-ones as C.N.S. active agents. J Pharm Pharm Sci (2005) 0.75
Possible antioxidant and neuroprotective mechanisms of FK506 in attenuating haloperidol-induced orofacial dyskinesia. Eur J Pharmacol (2003) 0.75
FK506 as effective adjunct to L-dopa in reserpine-induced catalepsy in rats. Indian J Exp Biol (2003) 0.75
Anticancer Potential of Ginger: Mechanistic and Pharmaceutical Aspects. Curr Pharm Des (2016) 0.75
Protective effect of FK506 (tacrolimus) in pentylenetetrazol-induced kindling in mice. Pharmacol Biochem Behav (2003) 0.75
Reversal of triazolam tolerance and withdrawal-induced hyperlocomotor activity and anxiety by bupropion in mice. Pharmacology (2005) 0.75
Effect of 5-lipoxygenase inhibition on events associated with inflammatory bowel disease in rats. Indian J Exp Biol (2004) 0.75
Antinociceptive action of FK506 in mice. Indian J Exp Biol (2003) 0.75
Reversal of haloperidol-induced orofacial dyskinesia by quercetin, a bioflavonoid. Psychopharmacology (Berl) (2003) 0.75
Modulatory effect of neurosteroids in haloperidol-induced vacuous chewing movements and related behaviors. Psychopharmacology (Berl) (2007) 0.75